menu
    • menu
    [{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"VGXI","sponsor":"Sutro Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Partnership","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"VGXI","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"VGXI \/ Sutro Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"VGXI \/ Sutro Biopharma"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Sutro Biopharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sutro Biopharma \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Sutro Biopharma \/ BofA Securities"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Tianjin Tasly Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Licensing Agreement","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Tianjin Tasly Group","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Tianjin Tasly Group"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Collaboration","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sutro Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Luveltamab Tazevibulin","moa":"||Folate-alpha receptor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Sutro Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sutro Biopharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sutro Biopharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Luveltamab Tazevibulin

    Menu

    Luveltamab Tazevibulin

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sutro, Boehringer Partner on Cell-Free Biopharma Manufacturing Scale-Up

                            Details : The collaboration aims to commercial scale to manufacture Luvelta (luveltamab tazevibulin), Sutro’s Tubulin FRα-targeting ADC designed to treat a broad range of patients with ovarian cancer.

                            Product Name : Luvelta

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Boehringer Ingelheim GmbH

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Bio Announces Results from REFRαME-O1 Trial in Platinum-Resistant Ovarian Cancer

                            Details : STRO-002 (luveltamab tazevibulin), is a best-in-class FolRα-targeting ADC, is being investigated in clinical trials for ovarian cancers in combination with Pegfilgrastim.

                            Product Name : Luvelta

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma Starts Phase 2 Trial of Luvelta for Lung Cancer

                            Details : Luvelta (luveltamab tazevibulin) is an FOLR1 antagonist antibody-drug conjugate, which is being evaluated for the treatment of patients with non-small cell lung cancer.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 22, 2024

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial

                            Details : STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated for ovarian cancers in combination with Pegfilgrastim.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 30, 2024

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            VGXI

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            VGXI

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Sutro Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            VGXI, Sutro Partner to Support Sutro's Clinical Pipeline

                            Details : The partnership with Sutro Biopharma to support the clinical production of Luvelta (luveltamab tazevibulin), a novel FRα-targeting antibody-drug conjugate for the treatment of ovarian cancer.

                            Product Name : Luvelta

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            March 06, 2024

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Sutro Biopharma

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

                            Details : Sutro intends to use the net proceeds of this offering to fund research, clinical, and development of STRO-002 (Luveltamab Tazevibulin) with Neulasta for FOLR1-expressed Ovarian Neoplasms.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            February 04, 2024

                            Lead Product(s) : Luveltamab Tazevibulin,Pegfilgrastim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : BofA Securities

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma Begins REFRαME-P1 Trial with Luvelta in Pediatric CBF/GLIS AML

                            Details : Luveltamab tazevibulin, formerly known as STRO-002, is a FR alpha-targeting antibody-drug conjugate (ADC) for Pediatric Patients with CBF/GLIS acute myeloid leukemia.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            January 11, 2024

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study...

                            Details : STRO-002 (luveltamab tazevibulin), is a best-in-class folate receptor alpha (FolRα)-targeting ADC, is being investigated in a phase 1 clinical trial for ovarian and endometrial cancers. FDA has also granted the fast track designation for STRO-002.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            September 01, 2023

                            Lead Product(s) : Luveltamab Tazevibulin,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovari...

                            Details : Sutro’s proprietary and integrated cell-free protein synthesis platform XpressCF® and site-specific conjugation platform XpressCF+™ led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed ADCs.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            December 21, 2022

                            Lead Product(s) : Luveltamab Tazevibulin,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed

                            Sutro Biopharma

                            U.S.A arrow
                            Vietnam Medi-Pharm Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Expo...

                            Details : Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies.

                            Product Name : STRO-002

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : Luveltamab Tazevibulin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth